Loading...
•
Dec 31, 2024
Teva Q4 2024 Earnings Report
Teva announced strong financial results in Q4 and full year 2024, driven by generics and innovative portfolio growth.
Key Takeaways
Teva's Q4 2024 revenues were $4,229 million, a decrease of 5% compared to Q4 2023. The decrease was mainly due to an upfront payment of $500 million received in 2023 related to the collaboration on our duvakitug (anti-TL1A) asset, partially offset by higher revenues from our innovative products AUSTEDO, UZEDY and AJOVY, from generic products in all our segments and from the sale of certain product rights.
Q4 2024 revenues were $4,229 million, a decrease of 5% compared to Q4 2023.
Non-GAAP operating income in the fourth quarter of 2024 was $1,168 million representing a non-GAAP operating margin of 27.6%.
Net loss attributable to Teva and loss per share in the fourth quarter of 2024 were $217 million and $0.19, respectively.
The company continues to execute on the Pivot to Growth strategy.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comOther Activities Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
2025 outlook assumes a full year contribution from Teva api and our business venture in Japan and excludes the expected income from potential milestone payments from Sanofi in connection with the Phase 3 initiation of duvakitug.
Revenue & Expenses
Visualization of income flow from segment revenue to net income